ClinicalTrials.gg
Status unknownNCT04986176Updated Feb 18, 2022

HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients

A Phase 3 interventional study of HC-1119 and Placebo in COVID-19 Respiratory Infection, sponsored by Applied Biology, Inc.. Status unknown. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-02-18.

Sponsored by Applied Biology, Inc. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
602
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The primary purpose of this study is to evaluate the efficacy of HC-1119 as an adjuvant treatment for hospitalized COVID-19 male and female patients.

Read the detailed description

This study is designed as a prospective, superiority, interventionist, placebo-controlled, double-blinded, randomized parallel assignment study. The study evaluates the efficacy and safety of HC- 1119.

Participants will be screened for eligibility; the assessment should be completed prior to any randomization to avoid screening failures to a maximum extent. Eligible participants (men and women) will be randomized 1:1 between arms (HC-1119 and placebo). HC-1119 and placebo will be administered orally.

The dosing regimen is 160 mg daily for 14 consecutive days. All patients will receive in parallel the standard treatment for COVID -19, according to the institution's protocol.

An electronic program will be used to manage randomization and drug shipment. The whole process will be handled in a manner that is blinded for the treatment received to all involved study personnel. The study follow up period will be 28 days after the first treatment.

02

Conditions studied

  • COVID-19 Respiratory Infection

Browse trials for

03

In context

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's planned enrollment of 602 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Applied Biology, Inc. is the lead sponsor of 25 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Admitted to the hospital with symptoms of COVID-19.
  2. Male and females age ≥18 years old.
  3. Confirmed positive SARS-CoV-2, through existing RT-PCR test within 7 days prior to randomization.
  4. Patients with clinical status categorized of scores 4, 5, or 6 on the COVID-19 Ordinal Scale:

      1. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID - 19 related or otherwise);
      1. Hospitalized, requiring supplemental oxygen;
      1. Hospitalized, on non-invasive ventilation or high flow oxygen devices;
  5. Participant able to swallow 4 capsules sequentially of the medication under investigation/ placebo
  6. Coagulation: ≤ 1.5 ×, and APTT ≤ 1.5×ULN
  7. Women of must have negative results of plasma pregnancy test (serum HCG).
  8. Participant (or legally authorized representative) gives written prior to performing any study procedures.
  9. Participant (or legally authorized representative) agree that participant will not participate in another COVID-19 trial while participating in this study.

Exclusion criteria

Exclusion Criteria:

  1. Participant enrolled in another interventionist study for COVID -19 treatment.
  2. Patients requiring mechanical ventilation.
  3. Patients taking an anti-androgen of any type including: androgen depravation therapy, 5-alpha reductase inhibitors, etc, having last dose of treatment less than 3 months prior to screening.
  4. Patients who are allergic to the product or similar drugs (or any ).
  5. Patients has malignant tumors in the past 5 years, except for completed resected basal cell and squamous cell skin cancer and completely resected carcinoma in situ of any type.
  6. Patient with known serious cardiovascular disease:

    1. Heart Failure III.
    2. Heart Failure NYHA IV.
    3. Angina class III -Canadian cardiovascular Society.
    4. Angina class IV -Canadian cardiovascular Society
    5. Angina with recent onset of symptoms, whose symptoms started 30 days or less.
    6. Myocardial infarction the last 3 months.
    7. Stroke in the last 3 months.
  7. Patient with a history of seizures/epilepsy.
  8. Patient taking any medications (or combination of medications) that could induce seizures/epilepsy during the study period.
  9. Patient with uncontrolled medical conditions despite adequate medication, that could compromise participation in the study (e.g., uncontrolled hypertension, hypothyroidism, diabetes mellitus).
  10. Known diagnosis of (HIV), , active , treponema pallidum (testing is not mandatory).
  11. (ALT) or Aspartate Transaminase (AST) > 5 times the .
  12. Estimated (eGFR) \< 30 ml/min.
  13. Severe kidney disease requiring dialysis.
  14. Patient likely to transfer to another hospital within 28 days after hospitalization.
  15. Women of , defined as all women physiologically capable of becoming pregnant, unless using a highly effective method of (detailed in the study protocol) throughout the study and for 3 months after stopping treatment with HC-1119.
  16. Sexually active men who refuse to use a condom during intercourse while taking HC-1119 and for 3 months after stopping treatment.
  17. Pregnant, breastfeeding, or women planning to become pregnant 3 months after treatment with HC-1119
  18. Participant (or legally authorized representative) not willing or unable to provide
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
602 participants (estimated)

Study arms

  • Experimental
    HC-1119 + Usual Care

    4 (40mg) soft gel capsule, 160 mg total

    Drug: HC-1119

  • Placebo comparator
    Placebo + Usual Care

    4 soft gel capsule

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. All-cause mortality risk ratio assessed by the proportion of patient deaths in both study arms.

    The proportion of patients reaching score 8 (death) on the COVID-19 ordinal scale at any given time up to 28 days for both study arms.

    Time frame: 28 days

Secondary outcomes

  1. Recovery ratio assessed by measuring the proportion of recovered patients in both study arms.

    Recovery will be defined as reaching scores 1 (Not hospitalized, no limitations on activities) and 2 (Not hospitalized, limitation on activities and/or requiring home oxygen) on the COVID-19 ordinal scale.

    Time frame: 28 days

  2. Recovery ratio assessed by measuring the proportion of recovered patients in both study arms.

    Recovery will be defined as reaching scores 1 (Not hospitalized, no limitations on activities) and 2 (Not hospitalized, limitation on activities and/or requiring home oxygen) on the COVID-19 ordinal scale.

    Time frame: 14 days

  3. Post-randomization time to recover/alive hospital discharge assessed by the median days (interquartile range) of time to recover.

    The median days (interquartile range) of time to recover will be calculated based on the number of days subjects will lead to reach scores 1 and 2 in the COVID-19 ordinal scale.

    Time frame: 28 days

  4. Hazard ratio for death assessed by measuring the proportion of deaths by time in both study arms.

    The percentage of patients that reached score 8 (death) in the COVID-19 ordinal scale at any given time up to 28 days for both study arms will allow for the calculation of the hazard ratio for death.

    Time frame: 28 days

  5. Pharmacokinetics of HC-1119 assessed by area under the plasma concentration-time curve from time 0 to infinity (∞) (AUC0-∞)

    Time frame: 14 days

  6. Pharmacokinetics of HC-1119 assessed by area under the plasma concentration-time curve from time 0 to time t of the last measurable concentration (AUC 0-t)

    Time frame: 14 days

  7. Pharmacokinetics of HC-1119 assessed by peak concentration (Cmax)

    Time frame: 14 days

  8. Pharmacokinetics of HC-1119 assessed by peak time (Tmax)

    Time frame: 14 days

  9. Pharmacokinetics of HC-1119 assessed by elimination half-life (t 1/2)

    Time frame: 14 days

  10. Efficacy of concomitant therapies assessed by sensitivity analysis of the primary, and key secondary outcomes.

    Sensitivity analysis of the primary, and key secondary outcomes to evaluate the efficacy of concomitant therapy including off-label use of marketed medications that are intended as treatment for COVID 19 and are given to patient prior to and during the study.

    Time frame: 28 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2022; primary completion for Dec 2022, 8 months later.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 8 months is close to that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2021
First posted
Aug 2, 2021
StartEst.
Apr 15, 2022
Primary completionEst.
Dec 31, 2022
CompletionEst.
Dec 31, 2022
Last update
Feb 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04986176
Collaborators
Hinova Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Aug 2, 2021
Start date
Apr 15, 2022 (estimated)
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Feb 18, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion